Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Int J Cancer. 2014 Jun 13;136(2):452–461. doi: 10.1002/ijc.28994

Figure 3.

Figure 3

SN6j, the parental mAb of the chimeric anti-hENG mAb c-SN6j (also known as TRC105), is effective for suppressing metastasis and primary tumor of 4T1 breast cancer. (a) The GEMs with established tumors of 4T1 were treated by i.v. administration of SN6j (100 μg/mouse; n = 10) or an equal amount of an isotype-matched control IgG (CCL130; IgG1-κ; n = 10). The administration was performed at 2 day intervals as indicated by vertical arrows. Statistically significant (p < 0.05) experimental points are indicated by the star symbols (*). Abscissa indicates days after tumor inoculation. (b) The tumor-bearing GEMs were sacrificed 10 days after the last treatment and the lungs of individual GEMs were retrieved for measurement of metastasis.